Curriculum Architecture & Scientific Scope

Colloquium Tracks & Proffered Session Taxonomy

The Annual Spring Forum evaluates original basic, translational, and early-phase clinical research across four structured tracks. Abstract submissions, podium lectures, and poster defenses are organized according to the scientific taxonomy detailed below.

Track 01

Preclinical Discovery, Natural Products & Cytotoxicity

Focuses on early-phase drug screening, cellular mechanisms of action, and biological assays. This track convenes laboratory investigations into botanical extracts, phytochemical fractions, secondary metabolites, and synthetic derivatives evaluated for antiproliferative, apoptotic, and selective cytotoxic properties against tumor cell models.

In vitro screening of phytochemical extracts and secondary plant metabolites
Assays for programmed cell death, apoptosis, necrosis, and autophagic flux
Cell proliferation kinetics, clonogenic potential, and viability profiling
Mechanisms of cell cycle arrest and checkpoint modulation in tumor cells
Toxicology assays, IC50 benchmarking, and selective cytotoxicity indices
Preclinical formulations, solubility optimization, and vehicle controls
Track 02

Cancer Genomics, NGS & Molecular Biomarkers

Covers the application of high-throughput genetic sequencing, gene expression signatures, and molecular alterations in oncology. Research presented examines driver mutations, genomic instability, non-invasive biomarker assays, and computational pipelines used to define disease progression.

Whole-genome, exome, and targeted next-generation sequencing (NGS)
Liquid biopsy platforms: circulating tumor DNA (ctDNA) and RNA dynamics
Epigenetic alterations, DNA methylation, and histone modification assays
Biomarker assay validation and analytical detection thresholds
Single-cell RNA sequencing and spatial transcriptomic tumor profiling
Bioinformatics pipelines for oncogenic variant calling and curation
Track 03

Cellular Therapeutics & Immune Modulation

Evaluates synthetic cell constructs, adoptive cell transfer methodologies, and receptor-targeted immune strategies. The track centers on overcoming physical and biochemical immunosuppression within solid tumor beds and optimizing biological effector cells.

Chimeric antigen receptor constructs (CAR-T, CAR-NK, and TCR-T platforms)
Immune checkpoint signaling pathways and antibody co-stimulation
Tumor microenvironment (TME) remodeling and overcoming dense stroma
Synthetic cellular receptors, logic-gated circuits, and safety switches
Non-viral cellular delivery systems and ex vivo transduction protocols
Mitigation strategies for cytokine release syndrome and cellular toxicity
Track 04

Therapeutic Resistance & Rational Combination Regimens

Addresses molecular pathways of intrinsic and acquired drug resistance encountered during targeted intervention. Sessions evaluate secondary escape pathways, adaptive signaling feedback loops, antibody payloads, and combinatorial regimens designed to sustain therapeutic durability.

Acquired secondary mutations in kinase targets (e.g., EGFR, KRAS, BRAF)
Antibody-drug conjugates (ADCs): Linker mechanics, payload release, and uptake
Synthetic lethality screening and dual-inhibition therapeutic pairing
Compensatory bypass activation and phenotypic plasticity
Preclinical combinations of natural adjuvants with conventional agents
Translational bridge models: Patient-derived organoids and xenografts (PDX)
Submissions Open

Submit an Abstract Under These Tracks

Structured 250-word abstracts are accepted across Tracks 01–04 for oral address or synchronous digital poster defense. Submissions undergo double-blind peer review by the academic committee.

Scroll to Top